6533b822fe1ef96bd127d61e

RESEARCH PRODUCT

Targeted Therapies in Hepatocellular Carcinoma

Stefania CusenzaEugenio FiorentinoGioacchino AngaranoEnrico BronteChristian RolfoAntonio RussoV. Di MarcoAlberto FirenzeGiuseppe CiceroFabrizio BronteGiuseppe BronteT. Fontana

subject

DrugOncologySorafenibmedicine.medical_specialtyCirrhosisbusiness.industrymedia_common.quotation_subjectmedicine.medical_treatmentPharmacologymedicine.diseasedigestive system diseasesFood and drug administrationLiver diseaseInternal medicineHepatocellular carcinomamedicineIn patientbusinessAdjuvantmedia_commonmedicine.drug

description

Hepatocellular carcinoma (HCC) is one of the main causes of death in patients affected by chronic liver diseases. The awareness of the biomolecular mechanisms underlying the complex carcinogenic process led to the development of targeted molecules, which are able to block this process. Sorafenib is a tyrosine-kinase inhibitor, and currently, it is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of HCC. However, some studies have demonstrated the efficacy of single drug therapies or combination therapies. They showed an improvement with regard to overall survival, time to progression, and progression-free survival, although these therapies were not free from toxicity. Further studies on molecular mechanisms could provide a better understanding that will help us in the therapeutic management of HCC. Besides, it will allow us to develop management protocols in the adjuvant, neoadjuvant, and metastatic settings.

yearjournalcountryeditionlanguage
2015-01-01
https://doi.org/10.1007/978-1-4939-2047-1_12